Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
PropTech Investment Corporation II to Combine with Appreciate, Bringing Single Family Rental Marketplace & Management Platform, Renters Warehouse, to the Public Markets
-
Cantor Fitzgerald Reiterates Neutral Rating on TherapeuticsMD (TXMD)
-
UPDATE: Aytu Biosciences (AYTU) PT Lowered to $5 at Cantor Fitzgerald, "Overweight" Rating Reiterated, Analyst Expects "Upwards Earnings Revisions Should Drive Shares Higher"
-
Spero Therapeutics (SPRO) PT Slashed to $5 at Cantor Fitzgerald, Analyst Maintains "Overweight" Rating
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Mar 31
-
Form 13F-HR CANTOR FITZGERALD, L. For: Mar 31
-
Form 13F-NT CANTOR FITZGERALD SECURI For: Mar 31
-
Form 13F-NT Cantor Fitzgerald Europe For: Mar 31
-
Form 10-Q Cantor Fitzgerald Income For: Mar 31
-
Form SC 13G Cartesian Growth Corp Filed by: CANTOR FITZGERALD SECURITIES
-
Cantor Fitzgerald Reiterates Overweight Rating. $15 Price Target on ContraFect (CFRX), "Expect Upwards Earnings Revision to Move Share Higher"
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
UPDATE: Benchmark Downgrades Shift Technologies Inc. (SFT) to Hold
-
Lionheart Acquisition Corporation II (LCAPU) Enters Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald
-
Lionheart Acquisition Corporation II Enters into Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald L.P.
-
Cantor Fitzgerald Assumes Poseida Therapeutics, Inc (PSTX) at Overweight
-
Cantor Fitzgerald Assumes Harpoon Therapeutics (HARP) at Overweight
-
CF Acquisition Corp. VI (CFVI) and Rumble File Amended Registration Statement for Proposed Merger
-
CF Acquisition Corp. VI and Rumble Announce Filing of Amended Registration Statement in Connection with their Proposed Business Combination
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion"
-
Cantor Fitzgerald Reiterates Overweight Rating on Fortress Biotech (FBIO) on Q1 Report, "Risk-Diversification Remains Attractive "
-
Cantor Fitzgerald Reiterates Overweight Rating on Checkpoint Therapeutics (CKPT) on Q1 Report
-
Cantor Fitzgerald Reiterates Overweight Rating, $5 on PAVmed (PAVM), "Encourage Investors to Acquire PAVM Shares at Attractive Valuation"
-
BancTrust & Co. Investment Bank Announces Launch of U.S. Broker-Dealer Affiliate
-
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
-
ADDING and REPLACING First All Female-Founded Investment Platform, LUXUS, Gives Investors Opportunity to Invest in Rare Diamonds and Gems
-
First All Female-Founded Investment Platform, LUXUS, Gives Investors Opportunity to Invest in Rare Diamonds and Gems
-
Cantor Fitzgerald Reiterates Overweight Rating, $18 Price Target on Aravive (ARAV), "Peak Sales Potential of AVB-500 Remains Underappreciated"
-
SILVERSTEIN PROPERTIES ACQUIRES FLORIDA DEVELOPMENT SITE FROM 1754 PROPERTIES AND TRIANGLE CAPITAL GROUP
-
Cantor Fitzgerald Reiterates Overweight Rating. $5 Price Target on Cidara Therapeutics (CDTX), "We Believe Street Under-appreciated Sales Potential of CDTX's Two Pipeline Assets"
-
Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
-
Cantor Fitzgerald Maintains ProQR Therapeutics N.V. (PRQR) at Overweight with $3.50 Price Target
-
Orchid Island Capital Announces May 2022 Monthly Dividend and April 30, 2022 RMBS Portfolio Characteristics
-
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
-
TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health
-
Westwater Resources, Inc. Announces Results for First Quarter Ended March 31, 2022
-
Form 13F-HR/A CANTOR FITZGERALD INVEST For: Mar 31
-
Cartesian Growth Corporation II Announces Closing of $230 Million Initial Public Offering
-
Cartesian Growth Corporation II Announces Closing of $230 Million Initial Public Offering
-
Curaleaf (CURLF) PT Lowered to $14.60 at Cantor Fitzgerald
-
'Welcome Relief': 3 Analysts Discuss Pfizer's $11.6 Billion Deal to Acquire Biohaven (BHVN)
-
Biotech Acquisition (BIOT) and Blade Therapeutics Announce Effectiveness of Registration Statement, Signs $75M Committed Equity Financing
-
Depoliticizing Corporate America: Strive Asset Management Launches To Advance Excellence Capitalism Over ‘Stakeholder Capitalism’
-
Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combinat
-
Best Marijuana Stocks To Watch This Week In May
-
RedHill Biopharma (RDHL) Announces 10.57M ADS Direct Offering at $1.42/ADS
-
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
-
Form 40-17G CANTOR FITZGERALD SUSTAI
-
Cartesian Growth Corporation II (RENEU) Prices 20M Unit IPO at $10/unit

